Cancer Research forms an innate part of CPAA with the major objective comprising translational community based research projects. The analysis is validated and disseminated through publications in peer reviewed national and international journals, presentation in conferences and communicating the key messages to the community. The focus of the Research team is translational research in the realm of identification of ‘Predictive Markers’ in Oral Cancer’ and ‘Cervical Cancer’, and study the psychosocial effects of cancer on patients and family members.
CPAA is uniquely positioned to understand the psychological issues that arise when a family member is diagnosed with cancer. We conduct research on appropriate topics affecting patients, parents, children and siblings. Translational research is conducted on the genetic profile of an individual susceptible to cancer or protects them against cancer in the face of faulty risk enhancing habits.
CPAA conducts systematic scientific studies of cancer related issues, such as risk factors, epidemiology and psychosocial effects on patients with cancer and their loved ones including caregivers. The studies are conducted after prior ethical approval is granted from the relevant Institutional Ethics Committees.
A. Translational Research Studies:
Project 1: Identification of ‘Predictive Biomarkers’ and Virtual Screening of ‘Small Drug- like Molecules’ targeted to Oral Cancer.
Dr. Dhananjaya Saranath, Dr. Sultan Pradhan Dr.s Hetal Damani, Dr. Wendy D’Souza, Dr. Shaleen Multani, Dr. Subuhi Yete
Oral cancer is a high incidence cancer in India, constituting 34% of the global oral cancer burden. The major risk factors are tobacco/areca nut, alcohol and high risk Human Papilloma Virus; contributing 90% of the attributable risk to the cancer. However about 5-10% individuals with high risk life style develop oral cancer. Thus individual genomic variants may be used to identify individuals with high risk of developing oral cancer. The team investigated genomic variants represented as single nucleotide polymorphisms in long term tobacco habitués with and without oral cancer. The team also used an in silico approach to identify inhibitors for five prototype proteins deregulated in cancer, using the Maybridge HitFinderTM, AnalytiCon NATx and AnalytiCon MEGx libraries using the Schrödinger chemical simulation software to identify small molecule inhibitors targeted to the deregulated proteins, with pharmacokinetic profiles predicting ‘drug-likeness’ of the compounds.
Project 2: Development of HPV Screening Protocol as a part of CPAA’s Early Detection Programme
Dr. Dhananjaya Saranath, Bhavna Sharma, Neeta More
High risk Human Papilloma Virus (HR-HPV) detection protocol using State-of-the-art Hybrid Capture 2 System for detecting and typing of HPV types by PCR and nucleotide sequencing to indicate risk of cervical cancer. About 10,000 women in cancer screening camps were screened. The data defined 6.8% women HR-HPV positive, and 3% positive for low risk HPVs. A follow-up and counseling in HPV positive women is an on-going process.
B. Psychosocial Projects: To Study the Psychosocial Effect of Cancer On Patients And Family Members
RESEARCH PUBLICATIONS: (2012 – 2022)
2022: Hetal Damani Shah and Dhananjaya Saranath
Modern Research Dentistry, Published: June 03, 2022 Volume 7 – Issue 2
Oral cancer is a high incidence cancer with well-established risk factors including tobacco, alcohol, areca nut, and HR-HPV 16/18. Additional risk factors such as Single Nucleotide Polymorphisms (SNPs) associated with genetic susceptibility, disease progression and prognosis. A comprehensive review of clinically relevant SNPs is synopsized in the current article.
2022: Dr. Dhananjaya Saranath
SCRIBE, Annual Science Journal, Sophia College (Autonomous), Mumbai | Volume 3, 2022
Cervical cancer ranks as the second most common cancer in females in India with 123,992 new cases annually, and 77,348 deaths (25% of global burden). Every 7-8 minute a woman in India dies due to the cancer. Cervical Cancer is caused by High-Risk Human Papilloma Virus (HR-HPV) and is preventable by simple means of HPV vaccination.
2019: Shaleen Multani, Hetal Damani, Dhananjaya Saranath
J Biomedical Research,6(1), 25-33, 2019
Kalpana Sriraman, Rupali Kekane, Daksha Shah, Dhananjaya Saranath, Nerges Mistry
bio Rxiv (Online), 2019 | 470 – 476. Doi: http://dx.doi.org/10.1101/576
2018: Veena Mishra and Dhananjaya Saranath
Journal Womens Health, Issues7 Care 2018, 7:2. DOI: 10.4172/2325-9795.1000303
2018: Hetal Damani, Dr. Dhananjaya Saranath, Soma Das, Prashant S. Kharkar, Anjali A. Karande
2018. J. of Cellular Biochemistry, pp 1 – 12
2018: Rutuja Dhawde, Ragini Macaden, Dhananjaya Saranath, Kayzad Nilgiriwala, Appasaheb Ghadge, Tannaz Birdi
International J. Research and Public Health, 15, 1247-1262, 2018 |doi:10.3390/ijerph15061247
Subuhi Yete, Wendy D’Souza, Dhananjaya Saranath Oncology, 94(3), 133 – 141, 2018.
2017: Wendy D’Souza and Dhananjaya Saranath
OMICS A Journal of Integrative Biology, 21 (12), doi: 10.1089/omi.2017.0146
2017: Subuhi Yete, Sultan Pradhan, Dhananjaya Saranath
Cancer Genetics, 214-215, 16-25.
2017: Roshanak Khandanlou, Vinuthaa Murthy, Dhananjaya Saranath & Hetal Damani
J Mater Sci DOI 10.1007/s10853-017-1756-4
2017: Vanaja P. Shetty, Dhananjaya Saranath, Anju R. Dighe, Shubhada Pandya, Vivek Vasudev
International J Scientific and Research Publications, 8, 398-406, 2017.
2017: Anirvan Chatterjee, Kayzad Nilgiriwala, Dhananjaya Saranath, Camilla Rodrigues, Nerges Mistry
Tuberculosis, 107, 63-72, 2017.
2017: Kalpana Sriraman, Kayzad Nilgiriwala, Dhananjaya Saranath, Anirvan Chatterjee, Nerges Mistry Current Microbiology, 75, 394 – 400, 2017
2017:Roshanak Khandanlou, Vinuthaa Murthy, Dhananjaya Saranath and Hetal Damani
J Mater Sci | doi: 10.1007/s10853-017-1756-4
2015: Sanjukta Chakrabarti, Shaleen Multani, Jyoti Dabholkar, Dhananjaya Saranath
doi: 10.1007/s12032-015-0483-4 , 32:60-71, 2015.
2014: Dhananjaya Saranath and Aparna Khanna | Biomedical Research Journal, 1 (1), 2014.
2014: Editors–in-Chief: Dr. Dhananjaya Saranath & Dr. Aparna Khanna
April Issue Volume 1, Issue 1, pp1-85, 2014.
2014: Kavita Shalia, Dhananjaya Saranath, V K Shah | Journal of Clinical Laboratory Analysis, 1-8, 2014
2013: Anirvan Chatterjee, Purva Bhater, Dhananjaya Saranath, Nerges Mistry
PLoS One, 8 (1), 1-8, 2013 | doi:10.1371/journal.pone.0054717.
Karnik Dani K, Oswal K, Maudgal S, Saranath D Indian Journal Cancer 2013
2013: Asawari Gupta, Dhananjaya Saranath The National Medical J India, 26(3) 184-185, 2013
2012: Shailaja Gada Saxena, Dhananjaya Saranath
J Human Reproductive Sciences, 5 (3), 289-292, 2012.
2012: S. Gada-Saxena, K. Desai, L. Shewale, P. Ranjan, D Saranath
Reproductive BioMedicine Online, 25(2), 209 – 218, 2012.
2012: Abida Juwle, Dhananjaya Saranath
Medical Oncology, 29, 3272-3281, 2012 | doi: information: 10.1007/s12032-012-0294-9
2012: Renu Bhatnagar, Jyoti Dabholkar, Dhananjaya Saranath
Oral Oncology, 2012, 48 (9): 831-835, 2012 | DOI information: 10.1016/j.oraloncology.2012.03.007
2012: Mahadik SR, Lele RD, Saranath D, Seth A, Parikh V
Adipocyte 1(2): 101-1072, 2012.
2012:Chandralekha Tampi and Dhananjaya Saranath(Invited Chapter) In: Haematology Today. Eds.
MB Agarwal& SA Rathi, Publ by MB Agarwal, Mumbai, India, pp 469-479, 2012
2012: Satish Khadilkar, Rajesh Dabhi, Pramod Dhonde, Nilesh Nadkarni, Smita Kulkarni, Dhananjaya Saranath
Neurology Asia, 17(3), 213-217, 2012.
Kavita2012: Kavita Shalia, S M Doshi, S Parikh, P P Pawar, S S Divekar, S P Verma, R Mehta, T Doctor, V K Shah, Dhananjaya Saranath J Ass .Physicians India, 60, 34-38., 2012
ABSTRACTS AND POSTER PRESENTATIONS:
Dr. Veena Shukla Mishra, Dr. Dhananjaya Saranath. Psycho-oncology, 28(3), 629-634, 2019
Mallika Narayan , Veena Shukla Mishra, Dhananjaya Saranath.
Presented at in 2019 Kochi conference on Palliative care | Paper Awarded 2nd Prize.
Maudgal S, Han W | 44th Annual Meeting of Korean Cancer Association and 4th International Cancer Conference, Seoul-21st – 22nd June, 2018
Maudgal S, Han W, e-Poster presentation | UICC World Cancer Congress, Kuala Lumpur-1st-4th October, 2018
Maudgal S, e-Poster presentation | UICC World Cancer Congress, Kuala Lumpur-1st-4th October, 2018
Dr. Veena Shukla Mishra and Dr. Dhananjaya Saranath.
Presented at UICC 2018 conference, Kuala Lampur, Malaysia.
Dr. Veena Shukla Mishra and Dr. Dhananjaya Saranath.
Presented at UICC 2018 conference, Kuala Lampur, Malaysia. 16 participant
Methil B, Maudgal S, CANREHAB 2017 | Tata Memorial Hospital, Mumbai-7th-9th April, 2017
Ms. Masara Shameem, Dr. Veena Shukla Mishra and Dr. Dhananjaya Saranath (Study Completed), 2014
Veena Shukla Mishra, Shubha Maudgal, Stephanie C.P.M. Theunissen, Carolien Rieffe
Journal of Psychosomatic Research, 72 , 266–268, 2012
Click here to know more